MedTrace Logo

Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions

NCT03684707 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-09-26

No results posted yet for this study

Summary

Evaluation of the metformin drug effect as a drug that found to improve the quality of tissues, decrease signs \& symptoms of cancer, and decrease histo-pathological criteria of dysplasia.

This will be done by the aid of measuring salivary Micro RNA 31 \& 210 in saliva in addition to measure cyclin A2 as an immuno-histochemical analysis.

Conditions

  • Oral Cancer

Interventions

DRUG

Metformin Hcl 500Mg 24Hr Sa Tab

Glucophage 500 mg once daily

OTHER

starch tablet

starch tablets

Sponsors & Collaborators

  • Ain Shams University

    lead OTHER

Principal Investigators

  • Fathia Z. Zahran, PHD · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-15
Primary Completion
2019-06-15
Completion
2019-09-15
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03684707 on ClinicalTrials.gov